Health ❯ Healthcare ❯ Pharmaceuticals

Medications

GLP-1 Drugs Semaglutide GLP-1 Receptor Agonists Weight Loss Tirzepatide Wegovy Weight Loss Drugs Statins Alzheimer's Disease Cholesterol-lowering drugs

4 ARTICLES

last wk.

FDA Approves Takeda’s Orzeyful for Narcolepsy Type 1

The pill is the first oral orexin receptor 2 agonist designed to restore orexin signaling and improve daytime wakefulness in adults with narcolepsy type 1.

3 ARTICLES

last wk.

CVS Cuts MinuteClinic Weight‑Loss Visits to $29 and Centralizes Access to GLP‑1 Drugs

9 ARTICLES

3w ago

Large Observational Studies Link GLP‑1 Drugs to Lower Cancer Rates and Slower Progression

6 ARTICLES

2mo ago

EMS’s Ozivy Cleared by Anvisa as First Synthetic Semaglutide Pen After Patent Expiry

19 ARTICLES

2mo ago

Anvisa Registers Ozivy as Brazil’s First Synthetic Semaglutide Analogue

3 ARTICLES

2mo ago

Novo Nordisk Cuts Ozempic Price for Uninsured Canadians as Generics Hit Shelves

9 ARTICLES

2mo ago

Anvisa Halts Specific Lots of Cimed Statins and Hypofarma Dexamethasone

3 ARTICLES

3mo ago

Canada Expands Access to Semaglutide With Home Delivery and First G7 Generics

3 ARTICLES

3mo ago

Brazil Approves Yesintek as a Stelara Biosimilar for Autoimmune Diseases

6 ARTICLES

3mo ago

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

8 ARTICLES

3mo ago

FDA Approves Auvelity as First Non‑Antipsychotic for Alzheimer’s Agitation

4 ARTICLES

3mo ago

Lilly Shares Slip as Foundayo’s Second-Week Prescriptions Trail Wegovy

5 ARTICLES

4mo ago

Anvisa Recalls Hypofarma Dipyrone Lot and Suspends All Mali Produtos Para Saúde Lots Over Quality Breaches

6 ARTICLES

4mo ago

Mexico Renews Warning as Counterfeit GLP-1 Weight-Loss Drugs Spread Worldwide

Medications

FDA Approves Takeda’s Orzeyful for Narcolepsy Type 1

CVS Cuts MinuteClinic Weight‑Loss Visits to $29 and Centralizes Access to GLP‑1 Drugs

Novartis Returns to Sales Growth as New Drugs Offset Entresto Slump

FDA Approves Lipfendra, First Oral PCSK9 Pill to Lower LDL Cholesterol

FDA Approves First Oral PCSK9 Pill, Merck’s Lipfendra

Purified THC‑CBD Drug Cuts Agitation in End‑of‑Life Dementia, Trial Shows

Brazilian-Made Semaglutide Pen Ozivy Now on Sale

Employers and Insurers Pull Back Coverage for GLP‑1 Weight‑Loss Drugs

Large Observational Studies Link GLP‑1 Drugs to Lower Cancer Rates and Slower Progression

EMS’s Ozivy Cleared by Anvisa as First Synthetic Semaglutide Pen After Patent Expiry

Never miss stories about

Medications

Anvisa Registers Ozivy as Brazil’s First Synthetic Semaglutide Analogue

Novo Nordisk Cuts Ozempic Price for Uninsured Canadians as Generics Hit Shelves

Anvisa Halts Specific Lots of Cimed Statins and Hypofarma Dexamethasone

Canada Expands Access to Semaglutide With Home Delivery and First G7 Generics

Brazil Approves Yesintek as a Stelara Biosimilar for Autoimmune Diseases

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

FDA Approves Auvelity as First Non‑Antipsychotic for Alzheimer’s Agitation

Lilly Shares Slip as Foundayo’s Second-Week Prescriptions Trail Wegovy

Anvisa Recalls Hypofarma Dipyrone Lot and Suspends All Mali Produtos Para Saúde Lots Over Quality Breaches

Mexico Renews Warning as Counterfeit GLP-1 Weight-Loss Drugs Spread Worldwide

Never miss stories about

Medications